Table 1 Baseline characteristics of the patients included in this analysis (i.e., all patients experiencing an aura before at least one attack treated with study drug) presented separately for the four different triptans
From: Efficacy of frovatriptan as compared to other triptans in migraine with aura
Rizatriptan | Zolmitriptan | Almotriptan | Frovatriptan | ||
|---|---|---|---|---|---|
(n = 28) | (n = 24) | (n = 8) | (n = 57) | ||
Age (years) | 43 +/− 9 | 35 +/− 10 | 37 +/− 11 | 41 +/− 11 | |
Females | 89% | 88% | 100% | 91% | |
MIDAS | grade I | 4% | 0% | 0% | 4% |
grade II | 4% | 0% | 0% | 6% | |
grade III | 36% | 55% | 38% | 43% | |
grade IV | 57% | 46% | 63% | 48% | |
Attack duration >2 days | 46% | 41% | 63% | 44% | |